Success Metrics

Clinical Success Rate

60.0%

Based on 3 completed trials

Completion Rate

60%(3/5)

Active Trials

1(14%)

Results Posted

0%(0 trials)

Terminated

2(29%)

Phase Distribution

Ph phase_1

71%

Ph phase_3

14%

Ph phase_2

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

5(71.4%)

Phase 2Efficacy & side effects

1(14.3%)

Phase 3Large-scale testing

1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Terminated(3)

Detailed Status

Completed3

Terminated2

Withdrawn1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

60.0%

Most Advanced

Phase 3

Trials by Phase

Phase 15 (71.4%)

Phase 21 (14.3%)

Phase 31 (14.3%)

Trials by Status

terminated229%

withdrawn114%

completed343%

active_not_recruiting114%

Recent Activity

1 active trials

Showing 5 of 7

active_not_recruitingphase_3

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

NCT04851613

completedphase_1

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

NCT05383482

completedphase_2

Clinical Trials (7)

Showing 7 of 7 trials

NCT04851613Phase 3

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Active Not Recruiting

NCT05383482Phase 1

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

Completed

NCT04374630Phase 2

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Completed

NCT02177682Phase 1

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

Terminated

NCT02240212Phase 1

Study of Afuresertib Combined With Paclitaxel in Gastric Cancer

Completed

NCT02380313Phase 1

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

Withdrawn

NCT02235740Phase 1

A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)

Terminated

All 7 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 7